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Background: Glycopeptide antibiotics inhibit bacterial cell-wall synthesis, and are important for the treatment of
infections caused by multi drug-resistant strains of enterococci, streptococci and staphylococci. The main
mechanism by which bacteria resist the action of glycopeptides is by producing a modified cell-wall in which
the dipeptide D-Alanine-D-Alanine is substituted by D-Alanine-D-Lactate or D-Alanine-D-Serine. Recently, it has
been shown that inorganic phosphate (Pi) induces hypersensitivity to vancomycin in Streptomyces coelicolor
(which is highly resistant to the antibiotic in low-Pi media). This finding was surprising because the bacterium
possesses the entire set of genes responsible for vancomycin resistance (VR); including those coding for the
histidine kinase/response regulator pair VanS/VanR that activates the system.
Results: This work shows that high Pi amounts in the medium hamper the activation of the van promoters
and consequently inhibit VR in S. coelicolor; i.e. the repression effect being stronger when basic or acidic
forms of the nutrient are used. In addition, this work shows that lysozyme resistance is also highly regulated
by the Pi concentration in the medium. At least five different mutations contribute to the overcoming of this
repression effect over VR (but not over lysozyme resistance). Therefore, the interconnection of VR and lysozyme
resistance mechanisms might be inexistent or complex. In particular, two kinds of mutant in which Pi control of VR has
been lost (one class expresses the van genes in a constitutive manner; the other retains inducibility by vancomycin)
have been isolated and further characterized in this study. Sequencing revealed that the first class of mutation
conferred a single amino acid substitution in the second transmembrane helix of the VanS protein; whereas
the other class hampered the expression or activity of a putative homolog (SCO1213) to the staphylococcal
GatD protein. Complementation, phenotypic and bioinformatics analyses identified SCO1213, and its upstream
gene (i.e. murT), as relevant genetic determinants involved with VR in S. coelicolor.
Conclusion: The genomic approach of this study together with other genetic and phenotypic analyses has
allowed the identification of the uncharacterized murT-gatD Streptomyces genes and the characterization of
their involvement with the Pi control of VR in S. coelicolor.
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Antimicrobial resistance (AMR) is a critical health issue
today. Many important pathogens have become resistant
to all available antibiotics used clinically, a problem be-
coming even more serious considering the lack of new
antibiotics in development. Therefore, there is an urgent
need to develop new antimicrobial strategies against bac-
teria exhibiting AMR. Vancomycin is a glycopeptide
used as one of the last resort antibiotic treatments for
many life-threatening bacterial infections including those
caused by methicillin-resistant Staphylococcus aureus
(MRSA); a major killer in nosocomial infections [1].
However, vancomycin resistance (VR) has spread to S.
aureus and other important pathogens such as Entero-
coccus faecium and Enterococcus faecalis [2]. During the
last two decades, VR Enterococcus (VRE) has become a
major nosocomial pathogen worldwide, mainly due to
their adaptability in hospital environments and limited
treatment options. Numerous VR gene cluster types
have been identified in enterococci; VanA and VanB be-
ing the most prevalent clusters in clinical isolates.
VanA-type strains are resistant to vancomycin as well as
to other glycopeptides, such as teicoplanin. On the other
hand, VanB-type strains exhibit resistance to vancomycin
but retain susceptibility to teicoplanin and other ana-
logues (unless the VR gene cluster is first activated with
vancomycin). Therefore, the VanA gene cluster is char-
acterized by an inducible high level of resistance to both
vancomycin and teicoplanin (the two main glycopeptide
antibiotics used in the clinic) while the VanB cluster
confers inducible resistance only to vancomycin [3].
Worryingly, both VanA and VanB clusters are often lo-
cated in transferable and conjugative genetic elements,
such as Tn1546 and Tn1549 transposons [4]. Conse-
quently, dissemination of these clusters constitutes a
major health risk worldwide.
In addition to pathogens, the explosion in microbial
genome sequencing has also revealed the presence of Van
clusters in non-pathogenic bacteria; not only in
glycopeptide-producing actinomycetes such as Amycola-
topsis orientalis and Streptomyces toyocaensis, but also in
strains that do not produce any glycopeptide antibiotics,
such as Streptomyces coelicolor [5, 6]. This bacterium
holds a Van cluster (vanSRJKHAX) conferring inducible
resistance to vancomycin but not to teicoplanin (similar to
the phenotype shown in VanB-type VRE). Therefore, S.
coelicolor offers a safe and convenient model system for
the study of VanB-type glycopeptide resistance [5]. Previ-
ously, this specie has been widely used as a model for
studies on antibiotic production in the actinomycetes; i.e.
microorganisms producing over two-thirds of the clinic-
ally useful antibiotics of natural origin today and other
bioactive secondary metabolites, such as antifungal com-
pounds, antitumor agents and immuno-suppressants [7].In S. coelicolor, and other bacteria, the Van cluster is con-
trolled by a classical two-component system (VanS-VanR)
that regulates the transcriptional activation of all the genes
of the cluster. In the absence of vancomycin, constitutive
phosphorylation of the response regulator VanR is sup-
pressed by the phosphatase activity of VanS and as a result,
there is no transcription of the Van cluster. On exposure to
vancomycin (but not to teicoplanin, in the case of type B
strains), VanS activity switches from phosphatase to kinase,
resulting in the accumulation of phosphorylated VanR
that binds to the van promoters and activates transcrip-
tion, including that of the conserved vanSR and van-
HAX core genes. vanH encodes a dehydrogenase that
converts pyruvate to D-Lactate (D-Lac), vanA codes for
a ligase that binds D-Alanine (D-Ala) and D-Lac amino
acids and vanX encodes a dipeptidase that cleaves
D-Ala-D-Ala dipeptides to ensure that only altered
peptidoglycan precursors ending in D-Ala-D-Lac are
accumulated. Overall VanHAX enzymes collectively
reconstruct the bacterial peptidoglycan to terminate in
D-Ala-D-Lac, in place of the canonical D-Ala-D-Ala,
which is required for vancomycin binding and
antibiotic action. The binding of vancomycin to
D-Ala-D-Lac is reduced by approximately 1000 fold [8].
VanK is also required for VR in Streptomyces because
this protein adds the glycine branch to cell-wall precur-
sors ending in D-Ala-D-Lac. FemX, which is respon-
sible for adding glycine to the normal cell-wall
precursors ending in D-Ala-D-Ala, cannot perform this
reaction on the modified cell-wall precursors terminat-
ing in D-Ala-D-Lac [9]. VanJ is not involved in VR but,
in as yet unknown manner, is involved in teicoplanin
resistance in S. coelicolor [10].
Transcriptional regulation of VR is not as simple as a
couple of van promoters activated under the presence of
vancomycin by a single transcriptional regulator (i.e.
vanR). Recently, it has been demonstrated that VR in S.
coelicolor and Streptomyces lividans is highly influenced
by the inorganic phosphate (Pi) concentration of the cul-
ture medium. VR was essentially blocked in these bac-
teria with Pi concentrations above 0.25% [11, 12].
Interestingly, addition of Pi to the medium significantly
increased vancomycin sensitivity in both S. coelicolor
wild-type and ΔphoP mutant strains. Therefore, this
regulatory effect is not driven (in principle) by the main
Pi-responding transcriptional regulator characterized in
bacteria (i.e. PhoP) and alternative players may be
involved. The aim of this work is to study S. coelicolor
mutants that overcome the Pi-depending vancomycin
lethal effect so as to bring new insights into the interre-
lated role of Pi and VR. The work also aims to check if
the Pi control observed in the VR mechanism is
extended to other cell-wall acting compounds, such as
lysozyme, in S. coelicolor.
Table 1 Pi regulation of vancomycin and lysozyme resistance.
The concentration of the compounds is shown as μg per mL.
(Pi = K2HPO4)
DifcoNA
Lys Van WT W1 W2 L1 L2 L4 L5
– – ++++ ++++ ++++ ++++ ++++ ++++ ++++
10 – ++++ ++++ ++++ ++++ ++++ ++ ++++
100 – ++++ ++++ ++++ ++ ++ + ++
500 – ++++ ++++ ++++ + – – +
– 50 ++++ ++++ ++++ ++++ ++++ ++++ ++++
10 50 ++++ ++++ ++++ ++ + – ++
100 50 ++ ++ ++ + – – +
500 50 ++ ++ ++ – – – –
DifcoNA + 1%Pi
Lys Van WT W1 W2 L1 L2 L4 L5
– – ++++ ++++ ++++ ++++ ++++ ++++ ++++
10 – ++++ ++++ ++++ ++ – – ++
100 – – – – – – – –
500 – – – – – – – –
– 50 – – – ++++ ++++ ++++ ++++
10 50 – – – – – – –
100 50 – – – – – – –
500 50 – – – – – – –
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Pi enhances the activity of vancomycin and lysozyme
against S. coelicolor
It has previously been shown that combination of vanco-
mycin with increasing concentrations of dipotassium
hydrogen orthophosphate (K2HPO4) from 0 to 1% aug-
ments the zone of growth inhibition against S. coelicolor
M145 in a disc diffusion assay [12]. The main Pi source
in that work was K2HPO4, which has a pH of ~ 8.4 when
1 g is dissolved in 100 mL of water (i.e. 1%). To investi-
gate whether the inhibitory effect on VR is specific for
PO43− or, for example, a pH effect, S. coelicolor M145
was grown in Difco Nutrient Agar (DifcoNA) with and
without 50 μg per mL of vancomycin in the presence of
various Pi salts, as follows: a) No Pi salt (pH~ 6.8), b) 1%
K2HPO4 (pH~ 8.2), c) 1% KH2PO4 (pH~ 5.4), d) 1%
K2HPO4 + KH2PO4 (pH~ 6.8), e) 1% Na2HPO4 (pH~
8.2), f ) 1% NaH2PO4 (pH~ 5.4), g) 1% Na2HPO4 +
NaH2PO4 (pH~ 6.8). The strain grew in a similar
manner in all media when no vancomycin was added,
indicating that these salts are non-toxic at a 1% concen-
tration. The strain also grew normally in the presence of
vancomycin when no Pi salt was added. However, no
growth occurred when any of the basic or acid sodium
or potassium forms of Pi were added to the vancomycin
supplemented media; although the growth was only
partially blocked with the addition of the neutral pH
salts. Therefore, this result discards a specific role for
potassium or sodium in the negative effect on VR and,
on the other hand, points to an important role for
monobasic or dibasic Pi in the observed inhibitory
effect.
To further test the negative effect of K2HPO4 (i.e. the
Pi salt used in the previous report by Santos-Beneit and
Martín; 12) in VR, the S. coelicolor M145 cells were sub-
jected to a Pi gradient experiment in DifcoNA supple-
mented with 50 μg per mL of vancomycin. For this
experiment, the spores were diluted to obtain (when
adding 100 μL of the spore suspension to the medium)
around 100 colonies growing per control plate. The
same amount of spores (i.e. 100 μL) was streaked in the
vancomycin supplemented cultures containing an in-
creasing gradient of Pi from 0 to 1% (with an increasing
unit of 0.1%). The result showed that no surviving col-
onies were observed when a Pi amount of 0.2% or higher
was added to the medium. In the condition of 0.1% Pi
the number of growing colonies was reduced to > 50%
(respect to the control condition of no Pi addition). In
summary, no extremely high amounts of Pi are required
to significantly decrease VR in S. coelicolor.
To check if this negative effect of Pi on VR is also ob-
served with other cell-wall acting compounds, such as
lysozyme, the resistance pattern of S. coelicolor was
tested in the presence of an increasing concentration oflysozyme (up to 500 μg per mL) and with or without
supplementation of 1% K2HPO4. As shown in Table 1 S.
coelicolor M145 cultures without Pi supplementation
grew with all lysozyme concentrations tested, while with
Pi supplementation growth was only observed on a lyso-
zyme concentration up to 10 μg per mL. Therefore, it
seems that lysozyme resistance is also regulated by
K2HPO4 in S. coelicolor.
Construction of a vancomycin inducible vanSR-vanJp-neo
fusion reporter system
To examine whether the negative effect of Pi on VR is
exerted at the promoter level a vancomycin reporter sys-
tem was constructed and named pVJ-neo (Fig. 1a). The
system carries a 2 kbp fragment of the S. coelicolor van
cluster containing the vanSR genes and the vanJ pro-
moter (vanJp). The aminoglycoside phosphotransferase
gene (neo), which confers resistance to both neomycin
and kanamycin, was transcriptionally fused to vanJp in
pVJ-neo. In parallel, a similar reporter construct was also
exploited (pHJH4; see Fig. 1a). This vector was previ-
ously shown to confer resistance to kanamycin in S. coe-
licolor in the presence of vancomycin (and other van
inducers) but not in their absence [13]. The two systems
differ in that the pVJ-neo system carries second copies
of the vanS-vanR gene system. This feature might be
Fig. 1 a Schematic representation of the pVJ-neo and pHJH4 reporter systems. b Checking of pVJ-neo and pHJH4 reporter systems in TSA plates.
The same amount of spores (106) of S. coelicolor strains containing pVJ-neo, pHJH4, pRL-neo and no vector were inoculated in TSA kanamycin
cultures (50 μg per mL) with or without 5 μg per mL of vancomycin. Plates were analysed after 4 days of growth at 30 °C. c-d Induction of pVJ-
neo using 96-well microplates. Different concentrations of vancomycin (0, 1, 5, 10 and 20 μg per mL) were added to TSA containing either no
kanamycin (c) or 50 μg per mL of kanamycin (d). In each well was added 106 spores of S. coelicolor W1. Plates were then incubated at 30 °C
during 52 h. Growth was determined by optical density (420 nm) using a BMG Fluostar Optima fluorometer. (e-f) S. coelicolor W1 cells were
grown during 6 days in Difco nutrient agar containing kanamycin (50 μg per mL) and vancomycin (50 μg per mL, upper panels) / (0.5 μg per mL,
lower panels) and with (f) or without 1% K2HPO4 (e) addition. Three different amount of spores (10
5, 106 and 107) were inoculated in each case.
g-h Same as e-f but with the addition of teicoplanin (5 μg per mL) instead of kanamycin
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divergent vanSR-vanJ promoter region. Also, having two
copies of the regulatory system should limit the recovery
of mutations in these immediate regulators in favour of
other classes of mutation. The vector pVJ-neo was intro-
duced in S. coelicolor M145 giving the strain S. coelicolor
W1. On the other hand, the vector pHJH4 was intro-
duced in S. coelicolor M145 giving S. coelicolor W2.Functionality of the two reporter systems was first
tested on kanamycin (50 μg per mL) supplemented TSA
(for the composition of this medium see Methods). This
medium has the advantage of having a relative high Pi
concentration (0.25% K2HPO4) with a neutral pH; there-
fore, the effect of a high or low pH is avoided. To have
an estimation of the amount of vancomycin needed to
induce resistance in this medium the MIC50 value was
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concentration value at which 50% of the isolates in a test
population are inhibited). The MIC50 value obtained in
TSA for both S. coelicolor W1 and W2 strains was around
5 μg per mL of vancomycin. Then, to check the function-
ality (and plausible differences of inducibility) of the two
reporter systems described above, S. coelicolor W1 and
W2 cells (and a control strain expressing the neo gene in a
constitutive manner; i.e. pRL-neo) were grown in TSA
supplemented with 50 μg per mL of kanamycin (with
either no vancomycin or 5 μg per mL of antibiotic). The
results (Fig. 1b) showed that both pHJH4 and pVJ-neo
vectors supported induction of the neo gene in a vanco-
mycin dependent manner (the strains grew in the plates
with vancomycin but not in the plates without the in-
ducer). Therefore, both pHJH4 and pVJ-neo vectors
provide a way to readily monitor induction of the vanJ
promoter via resistance to kanamycin.
The pVJ-neo system developed in this work was fur-
ther checked by growing the S. coelicolor W1 cells in a
polystyrene sterile 96-well plate with TSA medium and
different concentrations of vancomycin and/or kanamy-
cin. Plates were incubated at 30 °C for 52 h and growth
was determined by optical density using an automatic
microplate reader. Growth of the strain is shown in Fig.
1c-d (as a mean value of 8 replicates for each condition).
The amount of vancomycin that was required to confer
resistance to kanamycin ranged from > 1 to < 10 μg per
mL of antibiotic. Actually, induction of vanJ promoter
was only obtained when a vancomycin amount of 5 μg
per mL was added to the medium (i.e. others vanco-
mycin concentrations between 1 and 10 μg per mL were
not tested).
As a second approach to check the pVJ-neo system
the strength of vanJ induction was analysed using
DifcoNA (in which VR is not compromised in such low
vancomycin concentrations as with TSA). Different con-
centrations of vancomycin (0.5 or 50 μg per mL) and
K2HPO4 (0 or 1%) were added to the medium. As shown
in Fig. 1e, the W1 cells were able to induce the vanJ pro-
moter (i.e. conferring kanamycin resistance) with either
0.5 or 50 μg per mL of vancomycin when no Pi was
added to the medium. However, the induction of vanJ
promoter by vancomycin (either with 0.5 μg or 50 μg
per mL) was completely lost in the medium with 1%
K2HPO4 (Fig. 1f ). It is important to note that an amount
0.5 μg per mL of vancomycin does not kill the cells in
DifcoNA+ 1% K2HPO4 when no kanamycin is added
(which indicates that the lack of growth in the condition
of kanamycin addition is due to an insufficient vanJ pro-
moter activation and no because an inhibitory effect of
vancomycin at this concentration).
To determine whether induction of teicoplanin resist-
ance by vancomycin (VanB-type strains induce teicoplaninresistance in a vancomycin-dependent manner) is also
under a negative control by Pi in S. coelicolor the same ap-
proach was employed but, instead of adding kanamycin to
the cultures, teicoplanin was added. As previously, the
W1 cells were able to induce teicoplanin resistance with
0.5 or 50 μg per mL of vancomycin in DifcoNA but not in
DifcoNA+ 1% K2HPO4 (Fig. 1g-h). In summary, the re-
sults indicate that the induction range of the van pro-
moters in S. coelicolor is quite diminished in high Pi
concentrations.
Selecting mutants inducing vanJp at high pi
concentrations
A series of mutants were selected to gain insights into
the regulatory mechanisms conferring Pi control on the
activity of the van promoters. These mutants were se-
lected in TSA using two different inhibitory growth con-
ditions: a) kanamycin + 0.5 μg per mL of vancomycin
(i.e. ten times lower than the MIC50); b) kanamycin +
50 μg per mL of vancomycin (i.e. ten times higher than
the MIC50). As shown in Fig. 2a, the number of putative
mutant strains growing with the high vancomycin con-
centration was much higher than with the lower concen-
tration (indeed no colonies at all grew with the low
vancomycin amount in a first experiment). By increasing
the amount of the inoculum, and by several repetitions
of the experiment, four mutant strains were isolated in
the low vancomycin condition (see Fig. 2b-c). The isola-
tion of mutants with the capability to grow in the higher
vancomycin concentration was performed by picking 12
random colonies from those that were able to grow in
the experiment shown in Fig. 2a (i.e. using only the
panel of the W1 strain; see Fig. 2c). All the mutants se-
lected (termed “H” or “L” for high or low vancomycin
concentrations, respectively) passed two rounds of selec-
tion in their respective antibiotic concentrations in order
to select for stable genotypes/phenotypes. After selecting
the mutants, the MIC value of vancomycin (shown as μg
per mL of antibiotic) in TSA was calculated for all the
strains: a) W1, W2 and M145 ≤ 10. b) “H” mutants > 50
and < 100. c) “L” mutants > 100. These results indicate
that all the “L” strains are more resistant to vancomycin
than the “H” strains in the selective TSA medium.
As a first approach, to check the Pi control on VR in
the selected mutant strains, the growth of the parental
(W1, W2 and M145) and mutant strains was analysed in
both TSA and DifcoNA (with or without 1% K2HPO4)
using different concentrations of vancomycin (and with
or without kanamycin or teicoplanin to monitoring the
inducibility of the van promoters). All the “L” strains
and half of the “H” strains were able to grow (in a lower
or higher extent) in DifcoNA+ 1% K2HPO4 with 50 μg
per mL of vancomycin (see Fig. 2e); contrary to the par-
ental strains. Seven (H5, H11, H12, L1, L2, L4 and L5)
a b
c d
e f
Fig. 2 a Selection of mutant strains inducing vanJp in high Pi concentrations. 10
8 spores of S. coelicolor W1 and W2 strains were streaked in TSA
containing kanamycin (50 μg per mL) and vancomycin (50 or 0.5 μg per mL). Plates were grown at 30 °C until mutant colonies could be observed. b
Isolation of “L” mutants after increasing the amount of the inoculum (i.e. 109 spores) and repeating the experiment several times. In the figure is
shown the isolation of the L5 mutant as an example. c Scheme of the “H” and “L” mutants isolated and analysed in this study. d Scheme representing
the four main growth patterns observed for the strains in the growth conditions of the study, which are summarized with the next symbols (−, +, ++
and ++++). e-f Analysis of the growth of the mutant strains incubated at 30 °C during 4 days in: (e) DifcoNA with 1% K2HPO4 and 50 μg per mL of
vancomycin or in (f) DifcoNA with 1% K2HPO4 and 5 μg per mL of teicoplanin
Santos-Beneit BMC Genomics  (2018) 19:457 Page 6 of 16out of these strains showed a fully growth profile (++++)
according to the pattern shown in Fig. 2d, which indi-
cates that differences in the regulatory mechanisms
might exist between all the selected strains.
To further distinguish between mutants that main-
tained the inducibility by vancomycin from those show-
ing a constitutive van induction phenotype, the cells
were grown with teicoplanin and without vancomycin
(teicoplanin itself does not induce the van genes). Theresults showed mutants L1 and L5, in contrast to the
rest of the strains, with the ability to fully grow in teico-
planin without the inducer (see Fig. 2f ). A similar result
was obtained when kanamycin, instead of teicoplanin,
was used (data not shown). This result suggests that L1
and L5 mutants are probably inducing the van genes in
a constitutive manner. When testing the inducibility of
teicoplanin (or kanamycin) resistance with low (0.5) or
high (50) vancomycin concentrations only the “L”
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(except in DifcoNA+ 1% K2HPO4 + Van0.5 in which only
L1 and L5 grew; see Fig. 3a). Curiously, only one “H”
mutant strain (H11) was able to induce teicoplanin (and
kanamycin) resistance at the highest extent (++++) in
DifcoNA+ 1% K2HPO4 + Van50; none were able to do it
with 0.5 or 5 μg per mL of the antibiotic (see Fig. 3a-b).
These results indicate that the “L” mutants are not only
more resistant to vancomycin than the “H” strains, but
also have a much wider induction range of the van
promoters.
As a second approach, to detect additional differences
between the mutants, the cells (including the parental
strains) were subjected to a combination of Pi, lysozyme
and vancomycin in DifcoNA. Lysozyme resistance of all
the “L” mutants was decreased in relation with the par-
ental strains in all growth conditions; especially in L2a
b
Fig. 3 a Growth patterns obtained for the mutant and parental strains in Difc
K2HPO4 addition) and TSA supplemented with 5 μg per mL of teicoplanin. In
similar result was observed with the addition of kanamycin instead of
representation of the induction of teicoplanin resistance in the “L2” anand L4 (see Table 1). This indirect correlation between
VR and lysozyme resistance was not conserved in all the
“H” strains analysed. Actually, at least two “H” mutants
(H11 and H12) showed an increased resistance to lyso-
zyme in comparison to the parental strain in both low
and high Pi conditions (data not shown). Therefore, the
interconnection of these regulatory mechanisms might
be inexistent or complex.
Identification of gene polymorphisms associated with
increased VR in high Pi media
Since the acquired VR phenotypes of “L” and “H” strains
remained stable during sub-cultures it was expected to
find changes in the genome sequences of these strains.
As a first approach to identify the genomic alterations
responsible for the VR phenotypes Sanger sequencing of
the vanSR genes and all the van promoters of the clusteroNA supplemented with 5 μg per mL of teicoplanin (with or without 1%
all cases different concentrations of vancomycin were combined. A
teicoplanin and for this reason the data is not shown. b Schematic
d “H11” strains with TSA and DifcoNA+ 1% K2HPO4
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the strains L1 and L5 had acquired the same single nu-
cleotide polymorphism (SNP) during the selection pro-
cedure. This SNP resulted in the substitution of glycine
to aspartic acid in the amino acid 77 of the VanS protein;
which was not observed for the rest of strains (see
Table 2). Two different PCR reactions for each of the L1
and L5 strains were performed in order to exclude a
mistake of the polymerase reaction rather than a real
mutation in the chromosome (see Additional file 1:
Figures S1-S2). A different pair of primers (hybridizing
in the pVJ-neo vector backbone) allowed to specifically
sequencing the vanSR genes of the pVJ-neo vector (con-
tained in L1 but not in L5). No mutational changes were
detected in vanSR or the vanJ promoter of pVJ-neo in
L1 (see Table 2). Thus, only the chromosomal pair (from
the two set of vanSR genes present in L1) was mutated.
As a second approach to detect genomic alterations in
the mutant strains Illumina whole genome sequence
analysis of W1, W2, L2, L4, H1, H4, H5, H11 and H12
was performed (i.e. the rest of the strains were not se-
lected for the analysis). The L5 strain was also included
in the analysis as a control. The SNPs, insertions and de-
letions (InDels) of each individual strain (including W1
and W2) were identified relative to the reference strain
S. coelicolor M145. By subtraction relative to the respect-
ive parental strain, sequencing differences were identi-
fied in the genome sequences of each of the mutant
strains (i.e. L2 versus W1 and L4 versus W2). Only twoTable 2 Sanger and Illumina sequencing analyses of the “H” and “L”
both Illumina and Sanger sequencing analyses in each of the mutan
Mutation in chromosomal van genes
W1 No
W2 No
H1 No
H2 No
H3 No
H4 No
H5 No
H6 No
H7 No
H8 No
H9 No
H10 No
H11 No
H12 No
L1 VanS Gly77-Asp77
L2 No
L4 No
L5 VanS Gly77-Asp77specific mutations were detected in the selected “H”
strains in relation to its W1 parental strain. One of these
two mutations was found in SCO4474 of H5. This gene
codes for a putative cytochrome c biogenesis ResB-like
protein. The mutation (a SNP) resulted in the substitu-
tion of threonine to lysine in the amino acid 477 of the
protein (see Table 2 and Additional file 1: Figure S3).
The other mutation was detected in the SCO3167 gene
of H11; coding for a putative tetR-family transcriptional
regulator. The mutation produced a 5-nucleotide
insertion in the 3´ region of the SCO3167 ORF (i.e.
disrupting the translation of the full-length version of
the gene). Sanger sequencing using as control the W1
parental strain confirmed both mutations (see Additional
file 1: Figure S3-S4). The study of these two genes is not
included in this manuscript and it may form the basis of
future work.
Interestingly, L2 and L4 acquired during the selection
procedure a different SNP but in the same gene
(SCO1213). The SNP of L2 resulted in the substitution
of valine to glycine in the amino acid 120 of the protein,
while the SNP of L4 resulted in the change of the puta-
tive translation start triplet of SCO1213 from GTG to
GTT (i.e. which might lack the translation of the protein
at this triplet). Both mutations were confirmed by
Sanger sequencing using as control the respective W1
and W2 parental strains (see Additional file 1: Figures
S5-S7). No additional SNPs or InDels were detected for
L2 or L4 in comparison with W1 and W2, respectively.mutant strains. The table shows the mutations identified by
t strains
Mutation in vanSR of pVJ Mutation in other loci
No No
– No
No No
No ?
No ?
No No
No SCO4474 Thr477- Lys477
No ?
No ?
No ?
No ?
No ?
No SCO3167 (5nt-insertion)
No No
No No
No SCO1212 Val120-Gly120
– SCO1212 (GTG→GTT)
– No
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tion detected in L5 with the Sanger analysis was also
detected by the whole genome sequence analysis (see
Additional file 1: Figure S1). Similar to the L2 and L4
strains no additional variations were detected in L5 with
the Illumina analysis.
The identified SNP in vanS results in a constitutive
activation of the van system
The mutation in VanS substitutes a glycine residue by
an aspartic acid residue in the second transmembrane
segment of the protein (see Fig. 4a and Additional file 1:
Figure S8). To check the effect of this mutation on VR it
was made a series of complemented strains combining
mutated or not mutated genes in single copy or in paral-
lel with the wild type gene (see Fig. 4b). Important dif-
ferences in the patterns of van induction were observed
between the strains containing at least one mutated vanS
gene and the strains with only the wild type copy of the
gene. All the strains containing at least one mutated
vanS gene (in parallel or not with the wild type gene)
grew in the presence of kanamycin and/or teicoplanin
without the addition of vancomycin (see Fig. 4c). This
indicates that the mutation is dominant and produces a
constitutive activation of the van promoters.
SCO1213 is involved in VR
The second mutation implicated in VR of the “L” strains
occurred in gene SCO1213 (see Fig. 4d), which codes for
a homolog of the characterized GatD protein of S. aur-
eus (i.e. both containing a Type 1 glutamine amidotrans-
ferase central domain). The gatD product, along with
the product of its upstream gene (murT), amidates the
α-carboxylic group of the iso-D-glutamate residue at
position 2 of the peptide chain of the peptidoglycan [14,
15]. The murT-gatD genetic block is conserved in many
bacteria, including S. coelicolor. SCO1212 and SCO1213
share 28% identity / 45% similarity and 32% identity /
48% similarity with the S. aureus sequences of MurT and
GatD, respectively. The mutation identified in L2 substi-
tutes the amino acid 120 located within the putative
catalytic region of SCO1213 (Additional file 1: Figure
S9) and, according to a Psipred [16] inference, interferes
with the structure of a 7-amino acid beta strand
(Additional file 1: Figure S10). On the other hand, the
mutation identified in L4 disrupts the putative start
codon triplet of SCO1213 (i.e. avoiding translation from
this triplet). Therefore, both mutations seem to hamper
the function of the protein, the first affecting its catalytic
activity and the second affecting its expression. To verify
the role of the mutated SCO1213 gene in the
phenotypes of L2 and L4, the strains were complemen-
ted with plasmids pCOM-1213-L2 and pCOM-1213-L4,
respectively. These vectors contained a proper antibioticselection marker to be used in the respective strain
(apramycin in L2 and hygromycin in L4), the intact copy
of SCO1213 and the upstream gene (i.e. SCO1212) with
its own promoter (the intergenic region of SCO1212–13
has 23 nt; i.e. this segment is too short to comprise a
specific promoter for SCO1213). To exclude a role of
SCO1212 (i.e. murT) in the complemented strains the
control vectors contained the same inserts as the com-
plementation vectors with the exception of the SCO1213
ORF (see Methods section). The results with the com-
plemented strains are shown in Additional file 2: Table
S1. The wild type vancomycin and lysozyme resistance
phenotypes were almost fully restored in all the comple-
mented strains relative to the control strains; i.e. point-
ing to a specific role of SCO1213 (i.e. GatD) in the L2
and L4 phenotypes.
Overexpression of murT or gatD does not affect VR and
lysozyme resistance
According to previous transcriptomic analyses neither
SCO1212 (murT) nor SCO1213 (gatD) responded to the
addition of vancomycin to the medium [17]. The tran-
scription of both genes was maintained invariant before
and after this alteration (in contrast to the van genes
that were significantly activated by vancomycin). To gain
further information about the role of murT and gatD on
VR both genes were overexpressed with either a van in-
ducible promoter or a constitutive promoter (in sum to
the wild type copy pair). To this aim both genes were in-
dividually coupled to vanJ promoter in pVJ and pVJc
vectors (giving pVJ-1212/pVJ-1213 and pVJc-1212/
pVJc-1213, respectively). The four vectors were intro-
duced in S. coelicolor M145 (i.e. containing also the wild
type copies) and assayed in DifcoNA with different com-
binations of Pi, lysozyme, vancomycin and teicoplanin.
No differences were observed in any of the strains in re-
lation to the control strains in all conditions tested
(Additional file 3: Table S2). This result indicates that
exclusively the depletion of these genes, and no the over-
expression, produces a significant change in the VR and
lysozyme resistance profiles of the bacterium.
Analysis of growth of the mutant strains using a
microfluidic device
Interestingly, it has been noted that in most media tested
the size of colonies was smaller in L2 and L4 in com-
parison with the rest of the strains (data not shown). A
decrease in the size of the colonies was also described in
another high VR mutant strain (SCO2594::Tn5062) that,
in addition, was affected in cell-wall synthesis [17]. Fur-
thermore, a reduced growth was also reported in S. aur-
eus gatD depleted strains [14]. To get further insights on
the effect of vanS and gatD mutations on the growth of
S. coelicolor L1, L2, L4 and L5 strains a time-lapse
ab c
d e
Fig. 4 a Schematic representation of the localization of the mutation identified in L1 and L5 strains according to a predicted structure of the S.
coelicolor VanS protein by Hutchings and co-workers [18]. b Table summarising the results of L1, L5, WT and complemented strains according to
their capability to grow in teicoplanin containing plates without the presence of the inducer (i.e. vancomycin). c Plate showing the growth of the
developed vanS strains in Difco nutrient agar with 5 μg per mL of teicoplanin (and no vancomycin) after 6 days of incubation at 30 °C. d Genetic
organization of murT (green) gatD (blue) in S. coelicolor. The localization of the mutation of L2 in SCO1213 is shown with a vertical line. In the
image is also shown the conserved domains detected for the proteins according to the NCBI’s conserved domain database [28]. e Red overproduction
phenotype in the spore stocks of L1 and L5 in comparison to the rest of strains. In the picture, the spore stock of L5 is shown at the left and the spore
stock of W2 at the right
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vice was performed. In all cases TSB (the liquid form of
TSA) was constantly pumped into the microfluidic de-
vice with no vancomycin supplementation (to avoid an
effect of the antibiotic on the growth of the bacterium).
Growth of the spores was imaged by phase-contrast
time-lapse microscopy during 20 h (i.e. the images were
acquired every 10 min). The images showed an aberrant
growth in L2 and L4 in comparison with W1, W2, L1
and L5 (see Additional files 4, 5, 6, 7, 8 and 9: VideosS1-S6). In summary, tip elongation and growth rates
seem to be diminished in L2 and L4, which points to an
effect of gatD disruption, not only on VR, but also in the
growth of the bacterium.
Discussion
In this work the complexities of VR regulation have been
investigated in a model organism that belongs to the
group of bacteria that are the likely primordial source of
the Van clusters [6]. The strong Pi regulation on VR
Santos-Beneit BMC Genomics  (2018) 19:457 Page 11 of 16reported in S. coelicolor makes this organism a robust
and reliable model to test this phenomenon of an inter-
connected antibiotic resistance and nutrient regulation
mechanisms. A comparative genome sequence analysis
approach, based on specifically selected strains, has
allowed the identification of several genetic factors (i.e.
vanS and gatD) contributing to VR. These genetic fac-
tors, and also the Pi concentration in the medium, have
been shown to be important mediators not only for VR
but also for lysozyme resistance in S. coelicolor. In all the
strains analysed, vancomycin acted in synergy with lyso-
zyme to cause bacterial lysis. All the strains were less re-
sistant to lysozyme when vancomycin was present in the
medium, and/or vice versa. This is not strange since
both compounds target the cell-wall and, therefore, a
sum lethal effect is expected. The negative effect of Pi
over both VR and lysozyme resistance suggests common
mechanisms of regulation; however, mutations that were
positive for increasing VR were normally negative for
lysozyme resistance (see Table 1). This indirect correl-
ation between VR and lysozyme resistance was not con-
served in all the high VR strains analysed. Actually, at
least two “H” mutants showed an increased resistance to
lysozyme in comparison to the parental strain in both
low and high Pi conditions (data not shown). Therefore,
the interconnection of these regulatory mechanisms
might be inexistent or complex.
There are many examples in the scientific literature of
mutations in genes coding for a two-component system
that produce a constitutive activation of the members that
the own system positively regulates. However, it was unex-
pected to isolate two mutant strains, each from a different
parental strain, with exactly the same SNP. This was the
case with L1 and L5 mutants. These mutants were shown
to have a point mutation producing the same amino acid
substitution in the VanS protein. The mutation substitutes
a glycine residue by an aspartic acid residue in the second
transmembrane segment of the protein. Glycine is a small,
hydrophobic and non-charged amino acid while aspartic
acid is a negatively charged and hydrophilic amino acid.
Aspartic acid residues also create putative phosphorylation
sites. Therefore, a significant change in the 3D structure
of the protein and/or in the function of the protein is ex-
pected with this mutation. In a previous work, Hutchings
and co-workers [18] identified several mutations in vanS
producing a constitutive activation of the S. coelicolor Van
cluster. According to the authors these mutations had
something in common; all were loss-of-function muta-
tions. In this study, by a series of complementation experi-
ments, it has been shown that the mutation of L1 and L5
in vanS is dominant; producing a constitutive activation of
the van promoters even in the presence of the wild type
gene. Additional phenotypic differences were evident in
the strains carrying at least one vanS mutated gene;especially in terms of undecylprodigiosin production and
pigmentation of the spores (see Fig. 4e).
Increased resistance to vancomycin (i.e. conserving the
inducibility by the antibiotic) was acquired in two mu-
tant strains (L2 and L4) by two different SNPs; but in
the same gene (SCO1213). Other high vancomycin re-
sistant isolates, such as the “H” mutants, were evidenced
in this study. Some of these “H” strains showed a consti-
tutive activation phenotype (as L1 and L5) and others
were able to induce the van genes in a vancomycin
dependent manner (as L2 and L4). However, in contrast
with L2 and L4, none of the inducible “H” mutants (in-
cluding the most resistant H11 strain) were able to in-
duce teicoplanin resistance (or kanamycin) in TSA when
just as few as 0.5 μg per mL of vancomycin was added
to the medium. Something similar occurred in DifcoNA
+ 1% K2HPO4; but in all cases with a ten times higher
magnitude (i.e. 50 μg per mL of vancomycin was re-
quired to induce teicoplanin resistance -or kanamycin-
in H11, while just 5 μg per mL were sufficient in L2 and
L4; see Fig. 3a-b). These results are consistent with a
scenario in which the more Pi is added to the medium
the more vancomycin is needed for inducing van gene
expression. Actually at least five times lower amounts of
vancomycin were needed to induce fully teicoplanin re-
sistance (or kanamycin) in L2 and L4 when no Pi was
added to DifcoNA in comparison to the “H” mutant
strains (0.1 vs 0.5 μg per mL, respectively). Therefore, by
a yet unknown reason, L2 and L4 (both mutants in the
SCO1213 gene) are rare exceptions among the rest of
mutants analysed and can induce van gene expression
with a lower vancomycin concentration independently
of the Pi concentration.
The S. aureus GatD protein (i.e. the SCO1213 homolog)
together with MurT (i.e. the SCO1212 homolog) are re-
sponsible for the conversion of a glutamic acid residue to
a glutamine residue in the peptidoglycan of the bacterium
[14, 15]. The murT-gatD genes form a syntenic block that
is widespread among bacteria (see Additional file 1: Figure
S11), including the actinomycetes (such as the vanco-
mycin producer A. orientalis or the glycopeptide A47934
producer S. toyocaensis) and other Gram-positives like for
example Mycobacterium tuberculosis, Streptococcus pneu-
monia or Clostridium perfringens. GatD and MurT appear
to form a physically stable bi-enzyme complex and to
contain all domain functions required for amidation of
glutamic acid in the lipid-linked peptidoglycan precursor
Lipid II [14, 15]. MurT, which exhibits a typical Mur ligase
central domain including the ATP binding motif, may be
responsible for the recognition of the reaction substrates
(i.e. Lipid II and ATP), while GatD seems to provide the
catalytic subunit involved in the transfer of the amino
group from free glutamine to the peptidoglycan precursor
(see Fig. 4d). Amidation of peptidoglycan glutamic acid
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been shown to be required for efficient peptidoglycan
cross-linking in different bacteria, such as S. aureus and S.
pneumonia [14, 19]. Inhibition of amidation by depletion
of murT-gatD genes caused reduced growth rate, reduced
resistance to beta-lactam antibiotics and increased sensi-
tivity to lysozyme in S. aureus [14]. In S. pneumonia a mu-
tation in spr1443 (murT) was shown to confer resistance
to pneumophages [20]. Due to the high distribution of
murT-gatD genes among bacteria, additional physiological
roles for the amidation of peptidoglycan cannot be
discarded. Actually, in this work an uncharacterized effect
involving a mutation on gatD (i.e. SCO1213) has been
reported. Two different S. coelicolor gatD mutants (L2 and
L4) have been shown to be more resistant to vancomycin
than the parental strains, especially in high Pi conditions.
In addition, the two mutant strains showed increased sen-
sitivity to lysozyme and reduced growth rate (similar to
the phenotype described for a S. aureus murT-gatD de-
pleted strain). Overall, the strong impact of gatD muta-
tions on the growth rate of distinct bacteria suggests that
an amidated peptidoglycan may provide better substrates
for proteins that catalyze peptidoglycan biosynthesis [14].
Moreover, amidation of the peptidoglycan seems to in-
crease the binding affinity of several glycopeptides (such
as oritavancin and chloroeremomycin) to the amidated
versions of both Lipid II and its depsipeptide counterpart
(i.e. Lipid II-D-Lac) in comparison to the respective
non-amidated variants [21]. However, in contrast to the
observations with oritavancin and chloroeremomycin, en-
hanced binding affinity to amidated lipid II was not ob-
served with vancomycin in vitro [21]. Amidation of the
glutamic acid residues (which implies a reduction of the
number of cell wall carboxylate groups and a less nega-
tively charged surface) could also indirectly impact on the
incorporation of large amounts of negatively charged Pi
groups to the cell-wall (i.e. in the form of teichoic acids or
other Pi-rich cell-wall polymers) and as a result to affect
the Pi metabolism regulation of the bacterium. Whether
MurT-GatD (SCO1212–13) activity, together with the ef-
fect of large amounts of Pi, actually contributes to vanco-
mycin susceptibility in S. coelicolor through an increasing
of the antibiotic affinity for the amidated version of the
peptidoglycan precursor or through an interaction with
the Pi metabolism (or through an alternative mechanism)
is still unknown. Therefore, further work will be required
to determine the role of MurT-GatD in VR and/or Pi
regulation in S. coelicolor. Furthermore, it will be of great
interest to check whether a vancomycin-resistant S. aur-
eus (VRSA) strain (and/or VRE strains) conserves the Pi
control over the VR mechanism and, in that case, if a
depleted mutant in murT-gatD overcomes such negative
regulation. Understanding the mechanisms for tackling
the Pi-dependent VR repression effect might provideinsights for the development of new strategies against
antibiotic-resistant bacteria via lowering antibiotic use.
Conclusion
The results of this study show that high Pi amounts in
the medium hamper the activation of the van promoters
and consequently inhibit VR in S. coelicolor; i.e. the re-
pression effect being stronger when basic or acidic forms
of the nutrient are used. It is yet unknown if the regula-
tory effect of the nutrient interacts or not with the lyso-
zyme resistance mechanism that, in the same manner
than VR, is highly regulated by the Pi concentration of
the culture. Multiple factors, including those responsible
for constitutive activation of the Van system (such as the
vanS allele of L1/L5) and those yet unknown depending
on the SCO1213 (GatD) protein, contribute for an over-
taking of this Pi-dependent VR obstacle. Other genetic
determinants, such as the previously described SCO2594
gene [17] and those already identified in some of the “H”
mutant strains, are probably also involved with the
tackle of the vancomycin lethal effect in high Pi concen-
trations. However, none of the mutants analysed in this
study abolished the Pi control over the lysozyme resist-
ance mechanism of the bacterium. Therefore, the inter-
connection of VR and lysozyme resistance mechanisms
might be inexistent or complex.
Methods
Bacterial strains, plasmids and growth conditions
The Escherichia coli and S. coelicolor species used in this
work are listed in Table 3. All the bacterial strains have
been acquired from the Centre for Bacterial Cell Biology
(CBCB) collection. In Additional file 10: Table S3 is
shown all the primers used in this work. E. coli strains
were cultured and transformed using standard proce-
dures. The vanSR-J fragment for construction of pVJ
was amplified by PCR using the primers FSB29 (sense)
and FSB30 (antisense). The sequences for the restriction
enzymes KpnI and HindIII-NdeI were introduced in
FSB29 and FSB30, respectively. These primers amplified
a 2074-bp fragment encompassing the S. coelicolor
vanS-vanR genes and the divergent vanR-vanJ promoter.
Then, a KpnI–HindIII digested fragment was cloned into
pMS82, yielding pVJ (8.3 kbp). The promoter-less neo
gene was amplified by PCR using the primers FSB48
(NdeI) and FSB49 (HindIII); a further 822 bp NdeI–Hin-
dIII digested fragment was cloned into pVJ, yielding
pVJ-neo (9.1 kbp). The same strategy was used for the
construction of pVJc and the pVJc-neo derivative. For
pVJc the same FSB29 and FSB30 primers than for pVJ
were used, but instead of using total DNA from the wild
type strain it was used total DNA from the L5 mutant
strain. For pRL-neo the S. coelicolor rpsL promoter was
amplified by PCR using FSB88 (KpnI) and FSB89 (NdeI)
Table 3 Strains and plasmids used in this work
Bacterial strains Description Reference
E. coli DH5α E. coli standard strain; F′Ф80 LacZ ΔM15 [29]
E. coli ET12567 (pUZ8002) E. coli conjugative strain; dam, dcm, hsdS, cat, tet [30]
S. coelicolor M145 S. coelicolor parental strain; SCP1− SCP2− [22]
S. coelicolor W1 S. coelicolor M145 (pVJ-neo); HygR This work
S. coelicolor W2 S. coelicolor M145 (pHJH4); ApraR This work
S. coelicolor RL-neo S. coelicolor M145 (pRL-neo); HygR This work
S. coelicolor H1-H12 S. coelicolor M145 (pVJ-neo) suppressor strains; HygR This work
S. coelicolor L1 S. coelicolor M145 (pVJ-neo) suppressor strain; HygR This work
S. coelicolor L2 S. coelicolor M145 (pVJ-neo) suppressor strain; HygR This work
S. coelicolor L4 S. coelicolor M145 (pHJH4) suppressor strain; ApraR This work
S. coelicolor L5 S. coelicolor M145 (pHJH4) suppressor strain; ApraR This work
S. coelicolor L5-S S. coelicolor L5 (pVJ); ApraR, HygR This work
S. coelicolor L5-S* S. coelicolor L5 (pVJc); ApraR, HygR This work
S. coelicolor WT-S* S. coelicolor M145 (pVJc-neo); HygR This work
S. coelicolor L2–1213 S. coelicolor L2 (pCOM-1213-L2); ApraR, HygR This work
S. coelicolor L4–1213 S. coelicolor L4 (pCOM-1213-L4); ApraR, HygR This work
S. coelicolor L2-Con S. coelicolor L2 (pSET152-SCO1212); ApraR, HygR This work
S. coelicolor L4-Con S. coelicolor L4 (pMS82-SCO1212); ApraR, HygR This work
S. coelicolor M145-pVJ-1212 S. coelicolor M145 (pVJ-1212); HygR This work
S. coelicolor M145-pVJ-1213 S. coelicolor M145 (pVJ-1213); HygR This work
S. coelicolor M145-pVJc-1212 S. coelicolor M145 (pVJc-1212); HygR This work
S. coelicolor M145-pVJc-1213 S. coelicolor M145 (pVJc-1213); HygR This work
Plasmids Description Reference
pMS82 Integrative vector; phiBT1; HygR [31]
pSET152 Integrative vector; phiC31; ApraR [32]
pHJH4 Integrative vector containing vanJp-neo; phiC31; ApraR [13]
pVJ vanRS-vanJprom cloned in pMS82; Hyg
R This work
pVJ-neo Promoterless neo cloned in pVJ; HygR This work
pVJc L5 vanRS-vanJprom cloned in pMS82; Hyg
R This work
pVJc-neo Promoterless neo cloned in pVJc; HygR This work
pRL-neo rpsLprom cloned in pVJ-neo; Hyg
R This work
pCOM-1213-L2 SCO1212–13 cloned in pSET152; ApraR This work
pCOM-1213-L4 SCO1212–13 cloned in pMS82; HygR This work
pSET152-SCO1212 SCO1212 cloned in pSET152; ApraR This work
pMS82-SCO1212 SCO1212 cloned in pMS82; HygR This work
pVJ-1212 Promoterless SCO1212 cloned in pVJ; HygR This work
pVJ-1213 Promoterless SCO1213 cloned in pVJ; HygR This work
pVJc-1212 Promoterless SCO1212 cloned in pVJc; HygR This work
pVJc-1213 Promoterless SCO1213 cloned in pVJc; HygR This work
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(i.e. the Van fragment is substituted by the rpsL pro-
moter) giving pRL-neo (7.6 kbp). For construction of
pVJ-1212/pVJc-1212 and pVJ-1213/pVJc-1213, the
SCO1212 and SCO1213 genes were amplified usingprimers FSB201-FSB202 and FSB203-FSB204, respect-
ively, and introduced in either pVJ or pVJc after NdeI/
HindIII digestion. For the complementation of L2 and
L4 mutants a 2285 bp fragment encompassing not only
SCO1213 but also SCO1212 and its promoter region
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start triplet of SCO1212) was amplified by PCR. For L2
complementation the BamHI (FSB184-L2; forward pri-
mer) and EcoRV (FSB185-L2; reverse primer) restriction
sites were introduced via the primer sequences. For L4
complementation the KpnI (FSB184-L4; forward primer)
and HindIII (FSB185-L4; reverse primer) restriction sites
were introduced via the primer sequences. A BamHI–
EcoRV fragment was cloned into pSET152 to obtain
pCOM-1213-L2. A KpnI–HindIII fragment was cloned
into pMS82 to obtain pCOM-1213-L4. For construction
of the control vectors for L2 and L4 complementation
analyses the inserts (including the SCO1212 ORF and its
promoter region, but not the SCO1213 ORF) were amp-
lified by PCR as follows. Primers FSB184-L2 (forward;
BamHI) and FSB200 (reverse; EcoRV) were used for
amplifying the control insert for L2. After BamHI/
EcoRV digestion the DNA fragment was introduced in
pSET152 giving pSET152-SCO1212. Primers FSB184-L4
(forward; KpnI) and FSB201 (reverse; HindIII) were used
for amplifying the control insert for L4. After KpnI/
HindIII digestion the DNA fragment was introduced in
pMS82 giving pMS82-SCO1212.
BD Tryptic Soy Broth plus 1.5% agar (TSA) and Difco
Nutrient Agar (DifcoNA) were used as standard solid
media for growth of the Streptomyces strains. BD Tryptic
Soy Broth is a general purpose medium that contains (per
Liter): 17 g Bacto™ Tryptone (Pancreatic Digest of Casein),
3 g Bacto Soytone (Peptic Digest of Soybean Meal), 2.5 g
Glucose, 5 g Sodium Chloride and 2.5 g K2HPO4 (pH 7.3).
Difco Nutrient Agar is a moderately rich, general purpose,
solid medium that contains (per Liter): 3 g Beef extract,
5 g Peptone and 1.5% Agar (pH 6.8).
Vancomycin and teicoplanin susceptibility tests
The MIC (minimum inhibitory concentration) repre-
sents the value at which all the isolates in a test popula-
tion are inhibited. The MIC50 represents the value at
which ≥50% of the isolates in a test population are inhib-
ited. These values were determined by spreading a con-
fluent lawn of spores onto the medium containing a
range of the antibiotic. The number of growing colonies
was evaluated after 4 days of incubation at 30 °C. For
the rest of the analyses the different antibiotics and com-
pounds were added to the medium before the spore
inoculation.
Growth determination in 96-well plates
S. coelicolor W1 cultures were performed in TSA using
polystyrene sterile 96-well plates. To each well (containing
100 μl of medium) was added 5 μl of a stock dilution con-
taining 106 spores. Plates were then incubated at 30 °C
during 52 h. Growth was determined by optical density
(420 nm) using a BMG Fluostar Optima fluorometer.Illumina analysis
Genomic DNA was extracted from S. coelicolor cells
using the “salting-out” method described in Kieser et al.
[22]. The extracted DNA was further purified using the
DNeasy Mini Spin Columns of the Qiagen Blood &
Tissue Kit. The quality of DNA and ratio of absorbance
(A260/A280; A260/A230) was checked using a Nano-
Drop™ spectrophotometer.
A Qubit™ fluorometer was used in association with
both the Qubit™ dsDNA Broad Range and High Sensitiv-
ity kits to dilute the purified sample DNA in pure water
to 0.2 ng per μl. An Illumina® Nextera -XT kit library
prep kit was then used to prepare the DNA from each
Streptomyces strain for sequencing. 1 ng of DNA (in
5 μl) from each strain was used as starting material for
this process. Tagmentation of the DNA within the
sample was carried out to fragment the DNA and add
Illumina® adapters. This was followed by a PCR step, to
amplify fragments and add the indexes for sample multi-
plexing, and a bead-based clean up step. The Agilent®
BioAnalyzer was used with the High Sensitivity DNA kit
to check the quality and fragment lengths of the DNA
during processing. Most of the strains were sequenced
twice using different Indexes to provide adequate cover-
age across each genome. Bead-based normalization was
carried out and then samples were pooled and denatured
before loading onto the Illumina® MiSeq V3 cartridge
ready for sequencing. 2 × 300 paired end sequencing was
carried out using the 600 cycle V3 kit.
Data analysis
The Illumina Miseq raw sequence paired-end fastq files were
assessed for sequence quality using the FastQC (https://
www.bioinformatics.babraham.ac.uk/projects/fastqc/) pro-
gram. FastQC provides a simple way to perform qual-
ity control checks on raw sequence data, coming
from high throughput sequencing pipelines to assess
quality phred scores of sequencing data. The raw
fastq files were trimmed to remove base pairs from
the fastq reads that were deemed low sequence qual-
ity based on phred scores; with a phred score cut off
threshold of 20 from the 3′ end of fastq reads, using
the program Trimomatic [23]. The trimmed paired
end fastq reads from each of the strains sequenced
were mapped against the reference genome strain S.
coelicolor M145 using the aligner bowtie 2 [24]. The
sam files were converted to a binary bam file format
using the program SAMtools [25]. To detect SNP
(Single Nucleotide Polymorphisms) and Indels (Inser-
tions Deletions) the program VarScan [26] was used.
VarScan uses a robust heuristical and statistical
approach to call variants that meet desired thresholds
for read depth, base quality and statistical signifi-
cance. A reference based comparison method was
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generated from SAMtools. The reference strain S. coe-
licolor M145 was used to detect SNPs/Indels with the
VarScan program. To visualize each strain and to look
at both the mapped reads from the bam files and
SNP and Indels from the sequenced strains, IGV: In-
tegrative Genomics Viewer [27] was used. The vcf
files, which are generated using VarScan, allowed
visualizing both SNPs and Indels using IGV genome
viewer. In-house analysis methods were developed to
compare SNPs and Indels between strains.
Sanger sequencing
For Sanger sequencing fragments up to ~ 3 kbp were
amplified by PCR using as template total DNA from the
different strains. Then, primers were designed to
hybridize within the respective amplification products in
order to cover the sequencing of the entire product. To
distinguish between the sequences of the chromosomal
vanSR genes and those contained in the pVJ-neo vector
two different amplification products were performed as
follows: a) primers FSB135-FSB136 (hybridizing in the S.
coelicolor chromosome) were used to amplified a
2177 bp fragment encompassing just the chromosomal
vanSR genes; b) primers FSB90-FSB101 (hybridizing in
the pMS82 vector) were used to amplified a 3055 bp
fragment encompassing the vanSR genes and the vanJ
promoter of pVJ-neo vector. Sequencing data was ana-
lysed using the ContigExpress program launched from
Vector NTI Advance 10 (Invitrogen).
Time-lapse microscopy
The spores were loaded into B04A microfluidic plates
(ONIX, CellASIC) at 4 psi for 30 s, washed at 3 psi for
30 s and grown at constant media flow rate of 2 psi. In
all cases TSB (Tryptic Soy Broth) was used as liquid
medium. The images were acquired using a Nikon Ti
microscope equipped with a Nikon Plan Apo × 100/1.4
oil objective and FRAP-AI v. 7.7.5.0 software (MAG Bio-
systems, Molecular Devices). Images were acquired every
10 mins during 20 h and the movies were processed
using ImageJ (NIH) software. In all cases the videos
show bright field channel images displayed at 4 frames
per second.
Additional files
Additional file 1: Figure S1. SNP of vanS in L5 identified by both
Illumina and Sanger sequencing. Figure S2. SNP of the vanS
chromosomal gene in L1 identified by Sanger sequencing. Figure S3.
SNP of SCO4474 in H5 identified by both Illumina and Sanger
sequencing. Figure S4. Insertion in SCO3167 of H11 identified by both
Illumina and Sanger sequencing. Figure S5. SNP of SCO1213 in L2
identified by both Illumina and Sanger sequencing. Figure S6. SNP of
SCO1213 in L4 identified by both Illumina and Sanger sequencing.Figure S7. Sanger sequencing control reactions for the SCO1213
mutations in W1 and W2. Figure S8. Sequences of wild type and
mutated VanS proteins and alignment of the two sequences. Figure S9.
Sequences of wild type and mutated SCO1213 proteins and alignment of
the two sequences. The image at the bottom shows the localization of
the mutation of L2 in SCO1213 and the catalytic triad of the protein
according to the CDD: NCBI’s conserved domain database [28]. Figure
S10. PSIPRED prediction of SCO1213 protein products in WT and L2
strains (http://bioinf.cs.ucl.ac.uk/psipred/). Figure S11. STRING analysis of
the SCO1212-SCO1213 gene cooccurrence (https://string-db.org/). The
figure shows genes families whose occurrence patterns across genomes
show similarities. (PDF 1040 kb)
Additional file 2: Table S1. Analysis of the growth of L2 and L4
complemented strains grown in DifcoNA (with or without 1% K2HPO4
addition) and different concentrations of lysozyme, vancomycin and
teicoplanin. The concentration of the compounds is shown as μg per mL.
(DOCX 16 kb)
Additional file 3: Table S2. Analysis of the effect of coupling SCO1212
and SCO1213 to pVJ and pVJc on the growth of the next strains: SC100
(S. coelicolor M145-pVJ-1212; isolate 1), SC101 (S. coelicolor M145-pVJ-
1212; isolate 2), SC102 (S. coelicolor M145-pVJc-1212; isolate 1), SC103 (S.
coelicolor M145-pVJc-1212; isolate 2), SC104 (S. coelicolor M145-pVJ-1213;
isolate 1), SC105 (S. coelicolor M145-pVJ-1213; isolate 2), SC106 (S.
coelicolor M145-pVJc-1213; isolate 1), SC107 (S. coelicolor M145-pVJc-1213;
isolate 2) in DifcoNA (with or without 1% K2HPO4 addition) and different
concentrations of lysozyme, vancomycin and teicoplanin. The concentration
of the compounds is shown as μg per mL. (DOCX 15 kb)
Additional file 4: Video S1. Spores of W1 grown in the CellASIC ONIX
microfluidic chamber in the presence of TSB medium. The images were
acquired every 10 mins during 20 h. The video shows bright field images
displayed at 4 frames per second. (AVI 16079 kb)
Additional file 5: Video S2. Spores of W2 grown in the CellASIC ONIX
microfluidic chamber in the presence of TSB medium. The images were
acquired every 10 mins during 20 h. The video shows bright field images
displayed at 4 frames per second. (AVI 18898 kb)
Additional file 6: Video S3. Spores of L1 grown in the CellASIC ONIX
microfluidic chamber in the presence of TSB medium. The images were
acquired every 10 mins during 20 h. The video shows bright field images
displayed at 4 frames per second. (AVI 15541 kb)
Additional file 7: Video S4. Spores of L2 grown in the CellASIC ONIX
microfluidic chamber in the presence of TSB medium. The images were
acquired every 10 mins during 20 h. The video shows bright field images
displayed at 4 frames per second. (AVI 28754 kb)
Additional file 8: Video S5. Spores of L4 grown in the CellASIC ONIX
microfluidic chamber in the presence of TSB medium. The images were
acquired every 10 mins during 20 h. The video shows bright field images
displayed at 4 frames per second. (AVI 29210 kb)
Additional file 9: Video S6. Spores of L5 grown in the CellASIC ONIX
microfluidic chamber in the presence of TSB medium. The images were
acquired every 10 mins during 20 h. The video shows bright field images
displayed at 4 frames per second. (AVI 14438 kb)
Additional file 10: Table S3. Primers used in this work. (DOCX 16 kb)
Abbreviations
AMR: Antimicrobial resistance; D-Ala: D-Alanine; DifcoNA: Difco Nutrient
Agar; D-Lac: D-Lactate; MIC: Minimum inhibitory concentration;
MRSA: Methicillin-resistant Staphylococcus aureus; Pi: Inorganic phosphate;
SNP: Single nucleotide polymorphism; VR: Vancomycin resistance
Acknowledgements
I thank Professor Jose Antonio Salas (University of Oviedo) for coordinating
the VANRESTREP project and providing me with a space in his lab. I thank
Professor Jeff Errington (Newcastle University) for his support and for his
constructive corrections in the manuscript. I thank Dr. Hee-Jeon Hong
(University of Cambridge) for providing the pHJH4 plasmid. I thank Ian
Selmes (Newcastle University) and Lucy Eland (ICOS, School of Computing,
Newcastle University) for their support with the Illumina Sequencing. I thank
Santos-Beneit BMC Genomics  (2018) 19:457 Page 16 of 16Robert Stones (Bioinformatics Support Unit, Faculty of Medical Sciences,
Newcastle University) for his support with the bioinformatics analyses.
Funding
A Wellcome Trust grant (098374) to Professor Jeff Errington at the Center for
Bacterial Cell Biology of the Newcastle University (UK) supported part of this
work. A H2020-MSCA-IF-2016 European Union Fellowship to Fernando
Santos-Beneit (UE-18-VANRESTREP-740080) at the University of Oviedo
(Spain) supported other part of the work.
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
FSB performed the laboratory experiments, conceived the work and wrote
the paper. The author read and approved the final manuscript.
Ethics approval and consent to participate
Ethical approval was not required in this study. This analysis utilized open
access data.
Consent for publication
Not applicable.
Competing interests
The author declares that he has no competing interests.
Received: 4 January 2018 Accepted: 29 May 2018
References
1. Chang VS, Dhaliwal DK, Raju L, Kowalski RP. Antibiotic resistance in the
treatment of Staphylococcus aureus keratitis: a 20-year review. Cornea. 2015;
34(6):698–703.
2. Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-
resistant enterococci: is it time to divorce? J Antimicrob Chemother. 2013;
68(4):731–42.
3. Rossolini GM, Mantengoli E, Montagnani F, Pollini S. Epidemiology and
clinical relevance of microbial resistance determinants versus anti-gram-
positive agents. Curr Op Microbiol. 2010;13(5):582–8.
4. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to
vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;
319(3):157–61.
5. Hong HJ, Hutchings MI, Neu JM, Wright GD, Paget MS, Buttner MJ.
Characterization of an inducible vancomycin resistance system in
Streptomyces coelicolor reveals a novel gene (vanK) required for drug
resistance. Mol Microbiol. 2004;52(4):1107–21.
6. D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D,
Zazula G, Calmels F, Debruyne R, et al. Antibiotic resistance is ancient.
Nature. 2011;477(7365):457–61.
7. Hopwood DA. Streptomyces in nature and medicine. New York: Oxford Univ
Press; 2007.
8. Reynolds PE, Courvalin P. Vancomycin resistance in enterococci due to
synthesis of precursors terminating in D-Alanyl-D-serine. Antimicrob Agents
Chemother. 2005;49(1):21–5.
9. Hong H-J, Hutchings MI, Hill LM, Buttner MJ. The role of the novel fem
protein VanK in vancomycin resistance in Streptomyces coelicolor. J Biol
Chem. 2005;280(13):13055–61.
10. Novotna G, Hill C, Vincent K, Liu C, Hong HJ. A novel membrane protein,
VanJ, conferring resistance to teicoplanin. Antimicrob Agents Chemother.
2012;56(4):1784–96.
11. Santos-Beneit F, Ordóñez-Robles M, Martín JF. Glycopeptide resistance: links
with inorganic phosphate metabolism and cell envelope stress. Biochem
Pharmacol. 2017;133:74–85.
12. Santos-Beneit F, Martín JF. Vancomycin resistance in Streptomyces coelicolor
is phosphate-dependent but is not mediated by the PhoP regulator. J
Global Antimicrob Resist. 2013;1(2):109–13.
13. Kwun MJ, Novotna G, Hesketh AR, Hill L, Hong HJ. In vivo studies suggest
that induction of VanS-dependent vancomycin resistance requires bindingof the drug to D-ala-D-ala termini in the peptidoglycan cell-wall. Antimicrob
Agents Chemother. 2013;57(9):4470–80.
14. Figueiredo TA, Sobral RG, Ludovice AM, Almeida JM, Bui NK, Vollmer W, de
Lencastre H, Tomasz A. Identification of genetic determinants and enzymes
involved with the amidation of glutamic acid residues in the peptidoglycan
of Staphylococcus aureus. PLoS Pathog. 2012;8(1):e1002508.
15. Münch D, Roemer T, Lee SH, Engeser M, Sahl HG, Schneider T. Identification
and in vitro analysis of the GatD/MurT enzyme-complex catalyzing lipid II
amidation in Staphylococcus aureus. PLoS Pathog. 2012;8(1):e1002509.
16. Bryson K, McGuffin LJ, Marsden RL, Ward JJ, Sodhi JS, Jones DT. Protein
structure prediction servers at University College London. Nucleic Acids Res.
2005;33(Web Server issue):W36–8.
17. Santos-Beneit F, Fernández-Martínez LT, Rodríguez-García A, Martín-Martín S,
Ordóñez-Robles M, Yagüe P, Manteca A, Martín JF. Transcriptional response
to vancomycin in a highly vancomycin-resistant Streptomyces coelicolor
mutant. Future Microbiol. 2014;9(5):603–22.
18. Hutchings MI, Hong HJ, Buttner MJ. The vancomycin resistance VanRS two-
component signal transduction system of Streptomyces coelicolor. Mol
Microbiol. 2006;59(3):923–35.
19. Bui NK, Eberhardt A, Vollmer D, Kern T, Bougault C, Tomasz A, Simorre JP,
Vollmer W. Isolation and analysis of cell wall components from
Streptococcus pneumoniae. Anal Biochem. 2012 Feb 15;421(2):657–66.
20. Leprohon P, Gingras H, Ouennane S, Moineau S, Ouellette M. A genomic
approach to understand interactions between Streptococcus pneumoniae
and its bacteriophages. BMC Genomics. 2015;16:972.
21. Münch D, Engels I, Müller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G,
Grein F, Bendas G, Sahl HG, Schneider T. Structural variations of the cell wall
precursor lipid II and their influence on binding and activity of the
lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother.
2015;59(2):772–81.
22. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA. A Practical Guide to
Streptomyces Genetics. Norwich: John Innes Foundation; 2000.
23. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
sequence data. Bioinformatics. 2014;30(15):2114–20.
24. Langmead B, Salzberg S. Fast gapped-read alignment with bowtie 2. Nat
Methods. 2012;9(4):357–9.
25. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
Durbin R, 1000 Genome Project Data Processing Subgroup. The sequence
alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078–9.
26. Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, Weinstock
GM, Wilson RK, Ding L. VarScan: variant detection in massively parallel
sequencing of individual and pooled samples. Bioinformatics. 2009;25(17):
2283–5.
27. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G,
Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.
28. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY,
Geer RC, He J, Gwadz M, Hurwitz DI, et al. CDD: NCBI's conserved domain
database. Nucleic Acids Res. 2015;43(D):222–6.
29. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J
Mol Biol. 1983;166(4):557–80.
30. MacNeil DJ, Occi JL, Gewain KM, MacNeil T, Gibbons PH, Ruby CL, Danis SJ.
Complex organization of the Streptomyces avermitilis genes encoding the
avermectin polyketide synthase. Gene. 1992;115(1–2):119–25.
31. Gregory MA, Till R, Smith MC. Integration site for Streptomyces phage phiBT1
and development of site-specific integrating vectors. J Bacteriol. 2003;
185(17):5320–3.
32. Bierman M, Logan R, O'Brien K, Seno ET, Rao RN, Schoner BE. Plasmid
cloning vectors for the conjugal transfer of DNA from Escherichia coli to
Streptomyces spp. Gene. 1992;116(1):43–9.
